Search the NeLM

Medicines A-Z
Find key information about medicines by name (prototype)
NeLM news service
Submission of regulatory applications for lapatinib in combination with trastuzumab for HER2-positive metastatic breast cancer

Source: PharmaTimes

Date published: 20/02/2012 14:40

Summary
by: Nicola Pocock

According to a report by PharmaTimes, GlaxoSmithKline has submitted regulatory applications in Europe and the USA for the use of lapatinib (Tyverb®) in combination with trastuzumab for the treatment of patients with HER2-positive metastatic breast cancer that has progressed on prior treatment with trastuzumab.  No further details are available in the report.

About this library entry
Category: 8.1.5 Other antineoplastic drugs | Cancer: breast
NeLM area:  News
Link (free subscription required)

Preview your comment

Add new comment

Comment text:

Comments

There are no comments yet. You could be the first! You must be Logged In to comment.
Back